ESMO Open最新文献

{"title":"10P Established prognostic scores predict screen failure but not clinical outcomes in phase I oncology trials","authors":"O. Estacio, E. Malsem, G. McGuinness, M. Kesper, H. Gan, D. Kee, S. Parakh, S. Healy, A.J. Weickhardt","doi":"10.1016/j.esmoop.2026.107787","DOIUrl":"10.1016/j.esmoop.2026.107787","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107787"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"14eP Real-world efficacy and safety of dual and single HER2 blockade in early breast cancer: A multicenter study in Vietnam","authors":"H.B. Tran, M.C.T. Nguyen, Q.T.D. Phan, H.A. Dang, D.X. Ho","doi":"10.1016/j.esmoop.2026.107791","DOIUrl":"10.1016/j.esmoop.2026.107791","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107791"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"102P Comparative clinical and economic outcomes of triple metronomic chemotherapy plus low-dose nivolumab versus conventional induction chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase IV real-world superiority trial","authors":"V.B. Shah, A.D. Khadela","doi":"10.1016/j.esmoop.2026.107907","DOIUrl":"10.1016/j.esmoop.2026.107907","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107907"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"113P Hepatic arterial infusion chemotherapy combined with transcatheter chemoembolization, camrelizumab, and apatinib for BCLC stage C hepatocellular carcinoma: A retrospective study","authors":"W. Xue, D. Zhao, H. Zhang","doi":"10.1016/j.esmoop.2026.107917","DOIUrl":"10.1016/j.esmoop.2026.107917","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107917"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"44P Base-edited universal CAR7 T cells (BE-CAR7) in relapsed/refractory T cell acute lymphoblastic leukemia: Pooled phase I efficacy and safety","authors":"D.J. Halim, N.S. Goenawan","doi":"10.1016/j.esmoop.2026.107823","DOIUrl":"10.1016/j.esmoop.2026.107823","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107823"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2RO DR315, a novel CAIX/CD70 bispecific antibody-drug conjugate for metastatic clear cell renal cell carcinoma","authors":"T. Li , Y. Chen , G. Yao , Z. Zhou , W. Duan , J. Fang , W. Fu , S. Liu , X. Qian , M. Shao , Z. Wang , J. Yu , S. Ye , P. Zhou , Y. Fu , J. Yao , Y. Fang , X. Wen , Y. Huang","doi":"10.1016/j.esmoop.2026.107780","DOIUrl":"10.1016/j.esmoop.2026.107780","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107780"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148385909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"35P Beyond inhibition: Engineering membrane-anchored designer TIMPs as pleiotropic modulators of the tumor microenvironment and oncogenic signaling","authors":"M.H. Lee","doi":"10.1016/j.esmoop.2026.107814","DOIUrl":"10.1016/j.esmoop.2026.107814","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107814"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148385917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"117TiP Membrane-anchored tissue inhibitor of matrix metalloproteinase T1PrαTACE suppresses soluble CD30 shedding and enhances T cell cytotoxicity in Karpas299 cells via TACE inhibition and increased membrane-bound CD30","authors":"R. Tao","doi":"10.1016/j.esmoop.2026.107921","DOIUrl":"10.1016/j.esmoop.2026.107921","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107921"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148385940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years","authors":"A. Pretta,&nbsp;G. Rebecchi,&nbsp;G. Maddalena,&nbsp;F. Marmorino,&nbsp;P. Ziranu,&nbsp;F. Manoni,&nbsp;M.C. De Grandis,&nbsp;M. Carullo,&nbsp;P.A. Ferrari,&nbsp;C. Donisi,&nbsp;G. Randon,&nbsp;E. Perissinotto,&nbsp;A. Taravella,&nbsp;V. Nasca,&nbsp;F. Buggin,&nbsp;G. Pretta,&nbsp;P. Ciracì,&nbsp;F. Bergamo,&nbsp;C. Cremolini,&nbsp;S. Lonardi,&nbsp;F. Pietrantonio","doi":"10.1016/j.esmoop.2026.108244","DOIUrl":"10.1016/j.esmoop.2026.108244","url":null,"abstract":"<div><h3>Background</h3><div>Early-onset colorectal cancer (EOCRC) is increasing worldwide and exhibits clinical heterogeneity. Patients younger than 40 years may constitute a biologically distinct subgroup within EOCRC. We investigated whether ‘very early-onset’ metastatic colorectal cancer (VEOCRC, ages 30-39) exhibits specific clinical and genomic features compared with EOCRC in patients aged 40-49 and whether these differences lead to variations in survival from the time of metastatic diagnosis.</div></div><div><h3>Materials and methods</h3><div>We analysed the data of metastatic EOCRC patients in a multi-institutional database, divided into two predefined age groups: 30-39 years and 40-49 years. Overall survival (OS) from metastatic diagnosis was estimated using Kaplan–Meier methods, and hazard ratios (HRs) were calculated with Cox regression. Comprehensive genomic profiling was carried out using the Foundation Medicine next-generation sequencing platform (FoundationOne®). Key molecular alterations were compared using odds ratios (ORs). Baseline clinicopathologic characteristics were assessed using χ² or two-sided Fisher’s exact tests.</div></div><div><h3>Results</h3><div>A total of 264 patients were included (aged 30-39: <em>n</em> = 65; aged 40-49: <em>n</em> = 199). Median OS was shorter in patients aged 30-39 years than in those aged 40-49 years (30.0 versus 38.0 months; log-rank <em>P</em> = 0.0269; HR 0.67). A distinct genomic profile appeared in patients with VEOCRC, characterised by higher <em>KRAS</em> mutation rates (55.4% versus 42.0%; OR 1.71; one-sided <em>P</em> = 0.041) and fewer <em>APC</em> alterations (69.2% versus 82.0%; one-sided <em>P</em> = 0.024). <em>NRAS</em>, <em>BRAF</em>, <em>PTEN</em>, and <em>POLE</em> alterations were directionally consistent with a more aggressive biology, although event counts were limited. Clinically, overall Eastern Cooperative Oncology Group performance status (ECOG PS) distribution was similar (χ² <em>P</em> = 0.099), but ECOG PS 0 was more common in VEOCRC (89.1% versus 76.8%; <em>P</em> = 0.0468). Peritoneal metastases occurred significantly more frequently in patients aged 30-39 (32.3% versus 19.6%; <em>P</em> = 0.041). No differences were observed regarding liver, lung, or nodal involvement.</div></div><div><h3>Conclusions</h3><div>Patients aged 30-39 years constitute a biologically distinct subgroup within EOCRC, with shorter survival, <em>KRAS</em> mutation enrichment, fewer <em>APC</em> alterations, and increased peritoneal involvement. These findings support the emerging idea of an ‘ultra-young’, genomically driven CRC subtype, with implications for disease biology, risk assessment, and treatment development.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 7","pages":"Article 108244"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148327762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis","authors":"S. Camera,&nbsp;A. Vogel,&nbsp;M. Rimini,&nbsp;M. Ikeda,&nbsp;O. Abidoye,&nbsp;J. Lucchetti,&nbsp;L. Antonuzzo,&nbsp;J.W. Kim,&nbsp;F. Nichetti,&nbsp;A. Saborowski,&nbsp;T. Pressiani,&nbsp;C. Vivaldi,&nbsp;I.G. Rapposelli,&nbsp;F. Peeters,&nbsp;C. Braconi,&nbsp;D.J. Pinato,&nbsp;E. Tamburini,&nbsp;C. Pircher,&nbsp;S. Tamberi,&nbsp;F. Castet,&nbsp;A. Casadei-Gardini","doi":"10.1016/j.esmoop.2026.108248","DOIUrl":"10.1016/j.esmoop.2026.108248","url":null,"abstract":"<div><h3>Background</h3><div>Treatment options for advanced biliary tract cancers (BTCs) progressing after first-line chemoimmunotherapy remain limited. Whether platinum-based chemotherapy reintroduction can restore disease control is unknown. This study evaluates cisplatin-gemcitabine-durvalumab (CGD) reintroduction in patients with advanced BTC progressing during durvalumab maintenance.</div></div><div><h3>Methods</h3><div>A multinational cohort of patients with BTC received first-line CGD followed by durvalumab maintenance. Those progressing during maintenance and treated with CGD reintroduction or FOLFOX/XELOX were analyzed. Primary endpoints were overall survival (OS) and progression-free survival (PFS) in the CGD reintroduction group; secondary endpoints included survival outcomes from maintenance and second-line initiation, overall response rate, and disease control rate.</div></div><div><h3>Results</h3><div>Among 1258 patients treated with first-line CGD, 475 received durvalumab maintenance. After disease progression during maintenance (<em>n</em> = 309, 65.1%), 31 patients (6.5%) underwent CGD reintroduction, while 114 (24%) received FOLFOX/XELOX. Baseline characteristics were comparable between groups, except for bilirubin levels. After a median follow-up of 22.6 months [95% confidence interval (CI) 20.0-25.1], median OS was not reached in the reintroduction cohort, while median PFS was 13.3 months (95% CI 9.7-15.8) from first-line initiation. From durvalumab maintenance start, median OS remained not reached and median PFS was 7.1 months (95% CI 4.8-11.3). Following reintroduction, median OS and PFS were 10.5 months (95% CI 8.0-10.5) and 9.0 months (95% CI 5.5-10.2). Compared with FOLFOX/XELOX, CGD reintroduction was associated with significantly improved OS [hazard ratio (HR) 0.47; <em>P</em> = 0.006] and PFS (HR 0.44; <em>P</em> &lt; 0.0001) from first-line therapy start, as well as improved PFS from second-line treatment start (HR 0.60; <em>P</em> = 0.027). These findings were confirmed after multivariable and inverse probability of treatment weighting adjustment. Response outcomes were comparable between groups.</div></div><div><h3>Conclusions</h3><div>This is the first study evaluating CGD reintroduction in patients with BTC progressing during durvalumab maintenance. Although the retrospective design does not allow definitive conclusions, our findings suggest potential benefit in selected patients.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 7","pages":"Article 108248"},"PeriodicalIF":10.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}